Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

partially HLA-matched AdV/CMV/EBV-specific allogeneic T lymphocytes

Partially or closely human leukocyte antigen (HLA)-matched allogeneic cytotoxic T lymphocytes (CTLs), derived from cell lines, specifically reactive to the three human viruses adenovirus (AdV), cytomegalovirus (CMV) and Epstein-Barr virus (EBV), with potential antiviral activity. Upon infusion of the partially HLA-matched AdV/CMV/EBV-specific allogeneic T lymphocytes in immunocompromised patients or upon allogeneic hematopoietic stem cell transplantation (HSCT) in an immunodeficient recipient, these CTLs may kill AdV, CMV, and/or EBV-infected cells, and may prevent or reduce the severity of viral infections by these pathogens.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:allogeneic HLA-matched virus-specific T cell lines
allogeneic HLA-matched VSTs
allogeneic partially HLA-matched AdV/CMV/EBV-specific T cells
partially HLA-matched adenovirus/cytomegalovirus/Epstein-Barr virus-specific allogeneic cytotoxic T lymphocytes
partially HLA-matched AdV/CMV/EBV-specific allogeneic T cells
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search